Company news
Aurinia Pharmaceuticals Inc news in 2019
Aurinia Pharmaceuticals Inc's news releases, calls and decks from 2019, newest first.
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
December 11, 2019
Aurinia Prices US$166.7 Million Public Offering of Common Shares
December 8, 2019
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
December 3, 2019
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
November 13, 2019
Aurinia Announces Updates to the Board of Directors
November 12, 2019
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
November 6, 2019
Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019
November 5, 2019
Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome
October 30, 2019
Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility
October 15, 2019
Aurinia Establishes At-the-Market Facility
September 12, 2019
Aurinia Pharmaceuticals to Release Second Quarter 2019 Financial Results on August 6, 2019
July 31, 2019